US 12,419,783 B2
Drug eluting ocular implant
David S. Haffner, San Clemente, CA (US); Kenneth M. Curry, San Clemente, CA (US); Harold A. Heitzmann, San Clemente, CA (US); and David Applegate, San Clemente, CA (US)
Assigned to Glaukos Corporation, Aliso Viejo, CA (US)
Filed by Glaukos Corporation, Aliso Viejo, CA (US)
Filed on Oct. 1, 2020, as Appl. No. 17/061,372.
Application 17/061,372 is a continuation of application No. 15/613,994, filed on Jun. 5, 2017, granted, now 10,813,789.
Application 15/613,994 is a continuation of application No. 13/989,037, granted, now 9,668,915, issued on Jun. 6, 2017, previously published as PCT/US2011/061967, filed on Nov. 22, 2011.
Claims priority of provisional application 61/417,154, filed on Nov. 24, 2010.
Prior Publication US 2021/0015662 A1, Jan. 21, 2021
Int. Cl. A61F 9/00 (2006.01); A61F 9/007 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 9/00781 (2013.01); A61K 9/0051 (2013.01); A61K 9/2072 (2013.01); A61F 2210/0061 (2013.01); A61K 9/0092 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method for an intravitreal injection of an agent for the treatment of an ocular disorder, comprising:
advancing to a surface of a sclera of an eye a delivery apparatus comprising:
a proximal end;
a distal end;
a cannula containing one or more micro-tablets,
wherein the one or more micro-tablets have a density of about 0.7 g/cc to about 1.6 g/cc; and
an activator configured to expel the one or more micro-tablets from the cannula of the delivery apparatus via passage through the proximal end;
piercing the surface of the sclera to create a hole in the sclera;
further advancing said delivery apparatus thru said hole such that said proximal end is within a vitreal cavity of the eye;
activating the activator to expel the one or more micro-tablets directly into the eye; and
withdrawing the delivery apparatus from the eye, thereby treating the ocular disorder by delivery of the one or more micro-tablets.